Edition:
United States

Pharma Mar SA (PHMR.MC)

PHMR.MC on Madrid SE C.A.T.S.

1.66EUR
11:35am EDT
Change (% chg)

€0.01 (+0.61%)
Prev Close
€1.65
Open
€1.67
Day's High
€1.68
Day's Low
€1.65
Volume
369,372
Avg. Vol
558,005
52-wk High
€4.06
52-wk Low
€1.40

Chart for

About

Pharma Mar SA is a Spain-based company engaged in the bio therapeutic drugs manufacture. The Company focuses on research, development and marketing of bio-active principles, primarily from marine origin, for application in human diseases treatment, including antitumour, antiviral and immunomodulation, as well as tropical... (more)

Overall

Beta: 1.52
Market Cap(Mil.): €361.14
Shares Outstanding(Mil.): 222.65
Dividend: --
Yield (%): --

Financials

  PHMR.MC Industry Sector
P/E (TTM): -- 29.73 33.88
EPS (TTM): -0.13 -- --
ROI: -21.73 13.68 13.21
ROE: -67.52 15.46 15.18

BRIEF-Pharma Mar FY Net Loss Widens To 26.7 Mln Euros YoY

* FY NET LOSS 26.7 MILLION EUROS VERSUS LOSS 24.1 MILLION EUROS YEAR AGO

Feb 28 2018

BRIEF-Pharma Mar Announces Positive Results Of Its MI13004 Antibody Conjugate

* ANNOUNCES POSITIVE RESULTS OF ITS ANTIBODY CONJUGATE ACTIVE IN BREAST, OVARIAN AND GASTRIC CANCERS Source text for Eikon:

Feb 16 2018

BRIEF-Pharma Mar Licenses Marine-Derived Payloads To Seattle Genetics

* LICENSES FULLY SYNTHETIC MARINE-DERIVED PAYLOADS TO SEATTLE GENETICS FOR USE IN DRUG CONJUGATES

Feb 14 2018

BRIEF-Pharma Mar Says Phase III Trial With Zepsyre In Resistant Ovarian Cancer Not Met Its Primary Endpoint

* CORAIL PHASE III WITH ZEPSYRE IN RESISTANT OVARIAN CANCER HAS NOT MET ITS PRIMARY ENDPOINT Source text for Eikon:

Jan 18 2018

BRIEF-Pharma Mar Requests Re-Examination Process For Aplidin From EMA

* REQUESTS PROCESS OF RE-EXAMINATION FOR APLIDIN FROM THE EUROPEAN MEDICINES AGENCY (EMA)

Jan 03 2018

BRIEF-Pharma Mar Signs Distribution License Agreement For Aplidin In Israel

* SIGNS COMMERCIALIZATION AND DISTRIBUTION LICENSE AGREEMENT FOR APLIDIN WITH MEGAPHARM IN ISRAEL Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Jan 02 2018

Earnings vs. Estimates